A Rentschler Collaboration Story

Gene therapies are pioneering innovative approaches to disease treatment, with viral vectors proving particularly effective for delivery. To enhance patient access and treat a broader range of conditions, manufacturers face unique challenges impacting the quality, scalability, and cost-effectiveness of the end product.

Learn how a collaboration between Cytiva and Rentschler Biopharma facilitates the efficient and flexible production of viral vectors.

Cytiva offers CDMOs enhanced operational efficiency and flexibility and aims to improve lives globally.